Serotonin transporter polymorphism as a predictor for escitalopram treatment of major depressive disorder comorbid with alcohol dependence

Muhonen, Leea H.; Lahti, Jari; Alho, Hannu; Lönnqvist, Jouko; Haukka, Jari; Saarikoski, Sirkku T.

doi:10.1016/j.psychres.2010.07.039

Cited by 18 publications

(29 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, studies have been reported that the S allele is correlated with higher risk of depression (Lotrich and Pollock 2004), alcohol dependence (McHugh et al 2010), and their comorbidity (Nellissery et al 2003). Recently, a study of the treatment outcomes for patients with comorbid depression and alcohol dependence indicated that the LL genotype predicted greater antidepressant responses to escitalopram (3 months of treatment) as measured by the improvement in Montgomery-Åsberg Depression Rating Scale scores (Muhonen et al 2011).…”

Section: Genetic Variations Of Sert Affecting Responses To Escitaloprammentioning

confidence: 99%

Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter—a review of current understanding of its mechanism of action

Zhong¹,

Haddjeri

Sanchéz

2011

Psychopharmacology

View full text Add to dashboard Cite

show abstract

Section: Genetic Variations Of Sert Affecting Responses To Escitaloprammentioning

confidence: 99%

Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter—a review of current understanding of its mechanism of action

Zhong¹,

Haddjeri

Sanchéz

2011

Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Conversely, those with early onset AD and who carried the L allele had better drinking outcomes when treated with placebo 92. A recent study in patients with comorbid major depression and AD treated with escitalopram, an SSRI, indicated no 5-HTTLPR genotype effect on the Alcohol Use Disorders Identification Test as compared with memantine, a nonserotonergically acting medication 93. Wong et al (2008) conducted a small study to determine whether 5-HTTLPR and 5HT2C rs6318 moderated the influence of citalopram, an SSRI, on adrenocorticotrophic hormone levels in males with AD and controls.…”

Section: -Ht Genetics and Substance Use Disorder Treatmentmentioning

confidence: 99%

Polymorphisms of the serotonin transporter and receptor genes: susceptibility to substance abuse

Herman

Balogh²

2012

SAR

View full text Add to dashboard Cite

Serotonin (5-hydroxytryptamine [5-HT]) is an important neurotransmitter implicated in regulating substance-use disorder (SUD) acquisition, maintenance, and recovery. During the past several years, an abundance of research has begun discovering and describing specific 5-HT genetic polymorphisms associated with SUDs. Genetic variations in the 5-HT system, such as SLC6A4, HTR1B, HTR2A, HTR2C, HTR3 (HTR3A, HTR3B, HTR3C, HTR3D, and HTR3E), likely play a role contributing to SUD patient heterogeneity. The 5-HT transporter-linked polymorphic region S allele, located in SLC6A4, has now been modestly associated with alcohol dependence in two large meta-analyses. Additional 5-HT genes may also play a role but have not been extensively investigated. A limited number of SUD treatment studies have included 5-HT gene variation as moderating treatment outcomes, but the results have been equivocal. Future research on 5-HT addiction genetics should adopt whole-genome sequencing technology, utilize large study samples, and collect data from multiple ethnic groups. Together, these methods will build on the work already conducted with the aim of utilizing 5-HT genetics in SUD treatment settings.

show abstract

“…While the MADRS is commonly used to examine depression among those with AD (Muhonen et al, 2011, Muhonen et al, 2008, Gual et al, 2003), no studies have assessed its validity as a diagnostic tool for depression compared to a gold standard diagnostic tool, such as the SCID, in these patients. This study therefore aimed to examine 1) the validity of the MADRS among an inpatient group seeking treatment for AD through exploring its sensitivity, specificity, positive and negative predictive power at different thresholds compared to a SCID diagnosis of a depressive disorder; 2) whether the validity of the MADRS differs by type of SCID-based diagnosis of depression ( i.e.…”

Section: Introductionmentioning

confidence: 99%

The Validity of the Montgomery-Asberg Depression Rating Scale in an Inpatient Sample with Alcohol Dependence

Hobden

Schwandt

Carey

et al. 2017

Alcohol Clin Exp Res

View full text Add to dashboard Cite

Background The Montgomery-Asberg Depression Rating Scale (MADRS) is commonly used to examine depressive symptoms in clinical settings, including facilities treating patients for alcohol addiction. No studies have examined the validity of the MADRS compared to an established clinical diagnostic tool of depression in this population. This study aimed to examine: 1) the validity of the MADRS compared to a clinical diagnosis of a depressive disorder (using the Structured Clinical Interview for DSM-IV (SCID)) in patients seeking treatment for alcohol dependence (AD); 2) whether the validity of the MADRS differs by type of SCID-based diagnosis of depression; and 3) which items contribute to the optimal predictive model of the MADRS compared to a SCID diagnosis of a depressive disorder. Methods Individuals seeking treatment for AD and admitted to an inpatient unit were administered the MADRS at day 2 of their detoxification program. Clinical diagnoses of AD and depression were made via the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders-IV at the beginning of treatment. Results In total, 803 participants were included in the study. The MADRS demonstrated low overall accuracy relative to the clinical diagnosis of depression with an area under the curve of 0.68. The optimal threshold for balancing sensitivity and specificity identified by the Euclidean distance was >14. This cut-point demonstrated a sensitivity of 66%, a specificity of 60%, a positive predictive value of 50% and a negative predictive value of 75%. The MADRS performed slightly better for major depressive disorders compared to alcohol-induced depression. Items related to lassitude, concentration and appetite slightly decreased the accuracy of the MADRS. Conclusion The MADRS does not appear to be an appropriate substitute for a diagnostic tool among alcohol-dependent patients. The MADRS may, however, still be a useful screening tool assuming careful consideration of cut-off scores.

show abstract

Serotonin transporter polymorphism as a predictor for escitalopram treatment of major depressive disorder comorbid with alcohol dependence

Cited by 18 publications

References 34 publications

Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter—a review of current understanding of its mechanism of action

Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter—a review of current understanding of its mechanism of action

Polymorphisms of the serotonin transporter and receptor genes: susceptibility to substance abuse

The Validity of the Montgomery-Asberg Depression Rating Scale in an Inpatient Sample with Alcohol Dependence

Contact Info

Product

Resources

About